Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN-CLL: Zanubrutinib in Elderly, Treatment-Naïve CLL/SLL Patients
NCT07739459Phase 2Not yet recruiting
- Sponsor
- LYSARC
- Start
- Dec 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by LYSARC. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07739459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739459.